Compare AbbVie Inc (ABBV) vs EOG Resources Inc (EOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs EOG Resources Inc — how do they compare? AbbVie Inc trades at $253.67 (market cap $449.91B), while EOG Resources Inc trades at $136.99 (market cap $71.66B). The key difference: AbbVie Inc is far larger — about 6.3× EOG Resources Inc's market cap, and EOG Resources Inc pays the higher dividend (3.03%). Which is the better fit depends on your goals.
| ABBV | EOG | |
|---|---|---|
Market Cap | $449.91B | $71.66B |
Sector | Health | Energy |
52-Week High | $261.07 | $149.89 |
52-Week Low | $184.85 | $101.78 |
Enterprise Value | $513.38B | $76.12B |
Dividend Yield | 2.72% | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
EOG Resources trades at $134.54, up 2.88% today, with a bearish technical signal but strong fundamentals including a P/E of 12.72 and net income margin of 23.39%. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected August 5, 2026. Recent news highlights strong free cash flow potential and shareholder returns, while analyst consensus is a Buy with a $157 price target.
The outlook for EOG is positive due to robust profitability, consistent earnings beats, and favorable oil price trends. Key risks include volatile energy markets and high capital expenditures. With no sell ratings from analysts and a price target implying 17% upside, the stock presents a compelling opportunity for value-oriented investors despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →
